ST3GAL2 encodes a sialyltransferase that catalyzes the transfer of sialic acid to galactose residues in α-2,3 linkage, primarily targeting gangliosides and glycoproteins 1. This enzyme plays essential roles in multiple biological processes including melanoma maintenance, where ST3GAL2 and ST3GAL1 are upregulated and required for tumor growth by stabilizing glycoproteins like CD98hc through sialylation 1. In hematopoiesis, ST3GAL2 functions alongside ST3GAL1 in O-linked glycan sialylation of key hematopoietic markers including CD34, CD43, and platelet glycoproteins, with their coordinated expression being crucial for megakaryocyte proplatelet formation 2. The enzyme is critical for brain development and function, as ST3GAL2/ST3GAL3 double-null mice exhibit severe dysmyelination, reduced myelin proteins, impaired motor coordination, and cognitive disability 3. Metabolically, ST3GAL2 knockout mice develop late-onset obesity and insulin resistance due to altered ganglioside profiles in adipose tissue affecting insulin receptor sensitivity 4. Clinically, ST3GAL2 expression patterns are associated with cancer progression in various malignancies including oral squamous cell carcinoma 5, prostate cancer 6, and chr16 myeloid leukemia 7, making it a potential therapeutic target and biomarker.